Are Wall Street Analysts Bullish on Quest Diagnostics Stock?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 24 2025
0mins
Source: NASDAQ.COM
Company Performance: Quest Diagnostics (DGX) has outperformed the S&P 500 and SPDR S&P Health Care Services ETF over the past year, with a 35.9% increase in stock value compared to the broader market's 20.7% rise, driven by consistent demand, innovation, and strategic acquisitions.
Analyst Ratings and Expectations: Analysts maintain a "Moderate Buy" consensus on DGX stock, with an adjusted EPS forecast of $9.70 for fiscal 2025, and Mizuho Financial has raised its price target to $178, indicating potential upside from current levels.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MFG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MFG
Wall Street analysts forecast MFG stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 8.800
Low
38.88
Averages
38.88
High
38.88
Current: 8.800
Low
38.88
Averages
38.88
High
38.88
About MFG
Mizuho Financial Group Inc is a Japan-based company mainly engaged in the banking, trust banking, securities, and other financial services. The Company operates through five business segments: Retail & Business Corporations Company (RBC), Corporate & Investment Banking Company (CIBC), Global Corporate & Investment Banking Company (GCIBC), Global Markets Company (GMC), and Asset Management Company (AMC). The CIBC segment operates for clients of large corporate corporations, financial corporations and public corporations in Japan. The GCIBC segment operates for clients of overseas-affiliated Japanese companies and non-Japanese companies. The GMC segment is engaged in investment business in interest rates, equity, among others. The AMC segment is engaged in the development and provision of products that meet the asset management needs of clients from individuals to institutional investors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AI Investor Bullish on Microsoft and Broadcom Amid Market Turmoil
- AI Investment Strategy: An AI agent based on Anthropic's Claude models counterintuitively increased its positions in Microsoft and Broadcom, allocating 10% and 8% of the portfolio respectively, demonstrating high confidence in expected returns exceeding 20%, highlighting AI's unique advantage in risk assessment.
- Microsoft's Valuation Opportunity: Despite a 28% drop in Microsoft's stock price prior to the Iran ceasefire, Claude views its 20x forward P/E ratio as undervalued compared to the software sector average, indicating a market mispricing of its cloud platform, with expectations that growth from Azure and Copilot will make current valuation compression temporary.
- Broadcom's Market Dominance: Claude identifies Broadcom as the
See More
AI Agents Identify Microsoft and Broadcom as High-Conviction Buys Amid Market Volatility
- AI Investment Strategy: Anthropic's Claude model identified Microsoft and Broadcom as high-conviction buys following the Iran ceasefire announcement, leading to a surge in both stocks, showcasing AI's unique advantages in navigating market volatility.
- Microsoft Valuation Insight: Despite a 28% drop in Microsoft's stock price this year, Claude views its 20x forward P/E ratio as undervalued compared to the software sector average, indicating a market mispricing that could lead to significant future earnings recovery.
- Broadcom's Market Position: Claude allocated 10% of its portfolio to Broadcom, recognizing its 60%-80% share in the custom AI chip market, with projected orders reaching $100 billion by 2027, highlighting strong growth potential.
- Long-Term Growth Outlook: The AI model sees Microsoft and Broadcom as pivotal players in the next decade of AI development, and while the market remains cautious about semiconductor cyclical risks, Claude identifies structural growth inevitability.
See More
Medicare Payment Increase Boosts CVS Stock Recovery
- Impact of Medicare Policy: The CMS's finalized Medicare payment increase of nearly 2.5% significantly improves the profitability outlook for CVS and other healthcare stocks, leading to a stock price rebound compared to the previously proposed 0.09% increase.
- Upgraded Earnings Expectations: Analysts project CVS's earnings per share to reach between $7 and $7.20 in 2026, with the increase in Medicare payments likely enhancing CVS's profitability and boosting market confidence.
- Stock Valuation Potential: Currently trading at around 11 times forward earnings, CVS could see its stock price rise to $90 or $100 if it narrows the valuation gap with competitors like UnitedHealth Group, offering substantial investment returns.
- Stable Dividend Yield: With a forward dividend yield of 3.4%, CVS not only provides steady income but also attracts long-term investors, further supporting the upward momentum of its stock price.
See More
CVS Health Stock Rebounds on Improved Medicare Payment Rates
- Medicare Rate Increase: The Centers for Medicare & Medicaid Services (CMS) finalized a 2.5% increase in Medicare payment rates, significantly better than the previously proposed 0.09%, which is expected to enhance CVS Health's profitability outlook and boost investor confidence.
- Earnings Forecast Adjustment: Analysts project CVS Health's earnings per share (EPS) to reach between $7 and $7.20 in 2026, with the increased Medicare payments potentially driving double-digit earnings growth in 2027, further propelling the stock price upward.
- Valuation Gap: CVS Health's current stock price trades at about 11 times forward earnings, while peers like UnitedHealth Group trade at 15 to 20 times; if CVS can partially close this valuation gap, its stock price could reasonably rise to $90 or $100, offering substantial investment returns.
- Stable Dividend Yield: With a forward dividend yield of 3.4%, CVS Health not only provides steady returns but, combined with the positive changes in Medicare policy, presents an attractive investment opportunity.
See More
Anthropic's Overlooked Broadcom Agreement: Its Significance for Amazon and Beyond.
- Broadcom's Expansion: Broadcom has expanded its partnership with AI startup Anthropic, indicating a positive trend for the tech industry.
- Implications for Cloud Giants: This move is seen as a favorable sign for other major players in the cloud computing sector.
See More
Mayfair Gold Appoints New CFO Kevin Annett
- Executive Appointment: Mayfair Gold has appointed Kevin Annett as Chief Financial Officer effective April 7, 2026, bringing over 15 years of mining finance experience, including his recent role as CFO of North America at Barrick Mining, which is expected to significantly support the construction and production of the Fenn-Gib project.
- Financing Plan: Annett will invest approximately $250,000 through a non-brokered private placement, which is expected to be used to advance the Fenn-Gib gold project in Ontario, highlighting the company's commitment to the project and its potential economic benefits.
- Share Issuance: The private placement will result in the issuance of 58,000 shares to Annett at a price of $4.38 per share, reflecting the latest closing price on TSX-V, which is anticipated to provide funding support for further project development.
- Option Incentives: The company has also granted Annett 250,000 stock options with a strike price of $4.38, vesting over five years, aimed at incentivizing his contributions to unlocking the value of the Fenn-Gib project.
See More
AI Investor Bullish on Microsoft and Broadcom Amid Market Turmoil
- AI Investment Strategy: An AI agent based on Anthropic's Claude models counterintuitively increased its positions in Microsoft and Broadcom, allocating 10% and 8% of the portfolio respectively, demonstrating high confidence in expected returns exceeding 20%, highlighting AI's unique advantage in risk assessment.
- Microsoft's Valuation Opportunity: Despite a 28% drop in Microsoft's stock price prior to the Iran ceasefire, Claude views its 20x forward P/E ratio as undervalued compared to the software sector average, indicating a market mispricing of its cloud platform, with expectations that growth from Azure and Copilot will make current valuation compression temporary.
- Broadcom's Market Dominance: Claude identifies Broadcom as the
See More
AI Agents Identify Microsoft and Broadcom as High-Conviction Buys Amid Market Volatility
- AI Investment Strategy: Anthropic's Claude model identified Microsoft and Broadcom as high-conviction buys following the Iran ceasefire announcement, leading to a surge in both stocks, showcasing AI's unique advantages in navigating market volatility.
- Microsoft Valuation Insight: Despite a 28% drop in Microsoft's stock price this year, Claude views its 20x forward P/E ratio as undervalued compared to the software sector average, indicating a market mispricing that could lead to significant future earnings recovery.
- Broadcom's Market Position: Claude allocated 10% of its portfolio to Broadcom, recognizing its 60%-80% share in the custom AI chip market, with projected orders reaching $100 billion by 2027, highlighting strong growth potential.
- Long-Term Growth Outlook: The AI model sees Microsoft and Broadcom as pivotal players in the next decade of AI development, and while the market remains cautious about semiconductor cyclical risks, Claude identifies structural growth inevitability.
See More
Medicare Payment Increase Boosts CVS Stock Recovery
- Impact of Medicare Policy: The CMS's finalized Medicare payment increase of nearly 2.5% significantly improves the profitability outlook for CVS and other healthcare stocks, leading to a stock price rebound compared to the previously proposed 0.09% increase.
- Upgraded Earnings Expectations: Analysts project CVS's earnings per share to reach between $7 and $7.20 in 2026, with the increase in Medicare payments likely enhancing CVS's profitability and boosting market confidence.
- Stock Valuation Potential: Currently trading at around 11 times forward earnings, CVS could see its stock price rise to $90 or $100 if it narrows the valuation gap with competitors like UnitedHealth Group, offering substantial investment returns.
- Stable Dividend Yield: With a forward dividend yield of 3.4%, CVS not only provides steady income but also attracts long-term investors, further supporting the upward momentum of its stock price.
See More
CVS Health Stock Rebounds on Improved Medicare Payment Rates
- Medicare Rate Increase: The Centers for Medicare & Medicaid Services (CMS) finalized a 2.5% increase in Medicare payment rates, significantly better than the previously proposed 0.09%, which is expected to enhance CVS Health's profitability outlook and boost investor confidence.
- Earnings Forecast Adjustment: Analysts project CVS Health's earnings per share (EPS) to reach between $7 and $7.20 in 2026, with the increased Medicare payments potentially driving double-digit earnings growth in 2027, further propelling the stock price upward.
- Valuation Gap: CVS Health's current stock price trades at about 11 times forward earnings, while peers like UnitedHealth Group trade at 15 to 20 times; if CVS can partially close this valuation gap, its stock price could reasonably rise to $90 or $100, offering substantial investment returns.
- Stable Dividend Yield: With a forward dividend yield of 3.4%, CVS Health not only provides steady returns but, combined with the positive changes in Medicare policy, presents an attractive investment opportunity.
See More
Anthropic's Overlooked Broadcom Agreement: Its Significance for Amazon and Beyond.
- Broadcom's Expansion: Broadcom has expanded its partnership with AI startup Anthropic, indicating a positive trend for the tech industry.
- Implications for Cloud Giants: This move is seen as a favorable sign for other major players in the cloud computing sector.
See More
Mayfair Gold Appoints New CFO Kevin Annett
- Executive Appointment: Mayfair Gold has appointed Kevin Annett as Chief Financial Officer effective April 7, 2026, bringing over 15 years of mining finance experience, including his recent role as CFO of North America at Barrick Mining, which is expected to significantly support the construction and production of the Fenn-Gib project.
- Financing Plan: Annett will invest approximately $250,000 through a non-brokered private placement, which is expected to be used to advance the Fenn-Gib gold project in Ontario, highlighting the company's commitment to the project and its potential economic benefits.
- Share Issuance: The private placement will result in the issuance of 58,000 shares to Annett at a price of $4.38 per share, reflecting the latest closing price on TSX-V, which is anticipated to provide funding support for further project development.
- Option Incentives: The company has also granted Annett 250,000 stock options with a strike price of $4.38, vesting over five years, aimed at incentivizing his contributions to unlocking the value of the Fenn-Gib project.
See More
